Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up

BACKGROUND: The currently approved dose of darunavir/ritonavir is 800/100 mg once daily for PI-naïve patients, and 600/100 mg twice daily for PI-pretreated patients. However, in DRV-sensitive patients at baseline in the POWER 1/2 trials, similar rates of HIV RNA suppression (1 log reduction) were ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanzafame, Massimiliano, Lattuada, Emanuela, Rigo, Fabio, Hill, Andrew, Vento, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P290
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225444/
https://www.ncbi.nlm.nih.gov/pubmed/25397566
http://dx.doi.org/10.7448/IAS.17.4.19822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225444/
https://www.ncbi.nlm.nih.gov/pubmed/25397566
http://dx.doi.org/10.7448/IAS.17.4.19822

Ejemplares similares